A Phase 3 clinical study (NCT06110676) evaluating the efficacy and safety of LZM012 compared to secukinumab in patients with moderate to severe chronic plaque psoriasis reached its primary completion on 2025-04-30. This multi-center, randomized, double-blind, positive control trial enrolled 918 participants, marking a significant step towards assessing potential new treatment options for psoriasis.
Background
Secukinumab is a known treatment option for psoriasis. This study is designed to assess the efficacy and safety of an investigational drug, LZM012, in comparison to secukinumab for patients with moderate to severe chronic plaque psoriasis.
Trial design
The study (NCT06110676) is a multi-center, randomized, double-blind, positive control Phase 3 clinical study. It is designed to evaluate the efficacy and safety of LZM012 in comparison to secukinumab in patients with moderate to severe chronic plaque psoriasis. The trial enrolled 918 participants.
What this means
The primary completion of this Phase 3 study signifies that all data collection for the primary outcome measures has concluded. While specific efficacy and safety results are not yet publicly available, this milestone is crucial for the ongoing evaluation of LZM012 as a potential new therapeutic option for individuals living with moderate to severe chronic plaque psoriasis, benchmarked against an established treatment like secukinumab. Future disclosures of the trial data will provide comprehensive insights into its findings.
Source
The information regarding the primary completion of this trial was sourced from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT06110676, titled "A Study to Evaluate the Efficacy and Safety of LZM012," was noted with a primary completion date of 2025-04-30 on clinicaltrials.gov.